Medtronic is attending this week's annual symposium of Vascular and Endovascular Issues (VEITHsymposium), where it is presenting a number of new medical research insights.
The company will be sharing the findings of clinical studies and symposia on aortic, peripheral, endovenous and vascular embolisation therapies during the educational meeting, which runs from November 14th to 18th in New York.
“Medtronic will be sharing new aortic, peripheral, endovenous and vascular embolisation therapy data at this year's VEITHsymposium.“
For example, 12-month results from the ANCHOR registry will highlight the benefits that the Endurant II/IIs stent graft system can offer in combination with the Heli-FX EndoAnchor system in subjects with abdominal aortic aneurysm with aortic necks of less than ten mm.
Additionally, 30-day clinical outcomes on the investigational Valiant Navion device will be shared, showing how this minimally invasive thoracic endovascular aortic repair system can benefit patients with descending thoracic abdominal aortic aneurysm disease.
Jason Weidman, senior vice-president and president of Medtronic's aortic and peripheral vascular division, said: "The vast amount of data being featured this week underscores our commitment to durable, consistent and safe vascular procedures, as well as industry-leading clinical rigour and data transparency."
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices